Idiopathic Pulmonary Fibrosis

Jascayd

FDA Approves JASCAYD® (Nerandomilast) for Idiopathic Pulmonary Fibrosis — First New Therapy in Over a Decade

Boehringer Ingelheim’s JASCAYD® (nerandomilast) gains FDA approval for IPF, offering an oral PDE4B inhibitor with favorable tolerability and the first new treatment option in 10+ years.